期刊
BLOOD REVIEWS
卷 45, 期 -, 页码 -出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2020.100707
关键词
COVID-19; Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); Cytokine storm syndrome; Hemophagocytic lymphohistiocytosis; Idiopathic multicentric Castleman disease; Cytokine release syndrome
类别
This review compares the clinical features, diagnosis, and treatment approaches of COVID-CSS with other hematological CSS, emphasizing novel therapeutics targeting cytokines and cell signaling pathways. Comparison of inflammation markers and cytokine levels aims to establish a foundation for future diagnostic criteria of COVID-CSS.
A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a Cytokine Storm Syndrome (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS). Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS. We review the evidence for cytokine blockade and attenuation in these known CSS as well as the emerging literature and clinical trials pertaining to COVID-CSS. Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据